A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. Background: OSI-906 is a potent inhibitor of IGF-1R and IR tyrosine kinase ...
HAWTHORNE, Calif.--(BUSINESS WIRE)--OSI Systems, Inc. (NASDAQ: OSIS) (the “Company” or “OSI”) today announced its intention to offer, subject to market and other conditions, $400 million aggregate ...
HAWTHORNE, Calif.--(BUSINESS WIRE)-- OSI Systems, Inc. (OSIS) (the “Company” or “OSI”) today announced the pricing of its offering of $500 million aggregate principal amount of 0.50% convertible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results